Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Altiratinib |
Trade Name | |
Synonyms | DCC-2701 |
Drug Descriptions |
Altiratinib (DCC-2701) is an inhibitor of MET, VEGFR2, TIE2, and Trk that decreases endothelial cell survival and may inhibit cell proliferation and increase cell death in tumors expressing these factors (PMID: 26965451). |
DrugClasses | MET Inhibitor 59 Trk Receptor Inhibitor (Pan) 32 |
CAS Registry Number | 1345847-93-9 |
NCIT ID | C118290 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Altiratinib | Altiratinib | 1 | 1 |
Altiratinib + Bevacizumab | Altiratinib Bevacizumab | 0 | 0 |
Altiratinib + Dabrafenib | Altiratinib Dabrafenib | 0 | 0 |
Altiratinib + Trametinib | Altiratinib Trametinib | 0 | 0 |